Patent US3856935A successfully refreshed from Google Patents.
US3856935A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Oral typhoid vaccine and method of preparing the same
Assignee: Institut Zur Erforschung Der Infektionskrankheiten
•
Filing: 1973-02-12
•
Granted: 1974-12-24
•
Expires: 1993-02-12
Abstract
Abstract Salmonella typhi strain Ty 2 is subjected to ultraviolet light, and the mutants so produced are screened for selection of strains defective in the enzyme uridine diphosphogalactose-4-epimerase, and a live vaccine is prepared from the selected and carefully isolated strains in the usual manner. The strains are also identified by their sharply reduced galactokinase and galactose1-phosphate uridylyltransferase activity, as compared to the parent strain.
Inventors
- 👤 R Germanier
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 10:17
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/02; A61K39/025; A61K39/0275; A61K2039/54; A61K2039/541; A61K2039/542; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
29 words
THE AMOUNT OF SAID HARVESTED CELLS BEING SUFFICIENT TO IMPROVE THE RESISTANCE OF A PERSON TO INFECTION WITH SALMONELLA TYPHI AFTER ORAL INGESTION OF SAID SOLIDS BY SAID PERSON.
Claim 2
Dependent Claim
29 words
THE AMOUNT OF SAID HARVESTED CELLS BEING SUFFICIENT TO IMPROVE THE RESISTANCE OF A PERSON TO INFECTION WITH SALMONELLA TYPHI AFTER ORAL INGESTION OF SAID SOLIDS BY SAID PERSON.
Claim 3
Independent Claim
152 words
A METHOD OF PRODUCING AN ORAL TYPHOID VACCINE FREE FROM TENDENCIES TO REVERSION TO VIRULENCE WHICH COMPRISES: A. EXPOSING A VIRULENT STRAIN OF SALMONELLA TYPHI TO A MUTAGENIC AGENT UNTIL DELECTION MUTANTS DEFICTIVE IN THE ENZYME URIDINE DIPHOSPHOGALACTOSE-4-EPIMERASE ARE FORMED; B. INFECTING THE EXPOSED STRAIN WITH A SMOOTH-SPECIFIC BACTERIOPHAGE UNTIL THE SMOOTH BACTERIA PRESENT UNDEGO LYSIS WHILE ROUGH BACTERIAL SURVIVE BECAUSE THEIR RIUGH STRUCTURE DOES NOT PROVIDE RECEPTORS FOR SAID BACTERIPOBAGE; C. SEPARATING FORMED ROUGH MUTANTS IDENTIFIABLE BY THE SHARPLY REDUCED GALACTOKINASE ACTIVITY AND GALACTOSE-1 PHOSPHATE URIDYLYL TRANSFERASE ACTIVITY THEREOF AS COMPARED TO SAID VIRULENT STRAIN FROM OTHER SURVIVING ROUGH MUTANTS; D. CULTUTING THE SEPARATED MULTANTS; E. HARVESTING THE CELLS OF THE CULTURED MUTANTS; F. SUSPENDING THE HARVESTED CELLS IN A PROTECTIVE LIQUID MEDIUM CONSISTING ESSENTIALLY OF A DISPERSION OF SOLID CARRIER MATERIAL IN A VOLATILE LIQUID TO FORM A SUSPENSION; AND G. VOLATILIZING SAID LIQUID FROM THE SOLIDS IN SAID SUSPENSION,
Claim 4
Independent Claim
152 words
A METHOD OF PRODUCING AN ORAL TYPHOID VACCINE FREE FROM TENDENCIES TO REVERSION TO VIRULENCE WHICH COMPRISES: A. EXPOSING A VIRULENT STRAIN OF SALMONELLA TYPHI TO A MUTAGENIC AGENT UNTIL DELECTION MUTANTS DEFICTIVE IN THE ENZYME URIDINE DIPHOSPHOGALACTOSE-4-EPIMERASE ARE FORMED; B. INFECTING THE EXPOSED STRAIN WITH A SMOOTH-SPECIFIC BACTERIOPHAGE UNTIL THE SMOOTH BACTERIA PRESENT UNDEGO LYSIS WHILE ROUGH BACTERIAL SURVIVE BECAUSE THEIR RIUGH STRUCTURE DOES NOT PROVIDE RECEPTORS FOR SAID BACTERIPOBAGE; C. SEPARATING FORMED ROUGH MUTANTS IDENTIFIABLE BY THE SHARPLY REDUCED GALACTOKINASE ACTIVITY AND GALACTOSE-1 PHOSPHATE URIDYLYL TRANSFERASE ACTIVITY THEREOF AS COMPARED TO SAID VIRULENT STRAIN FROM OTHER SURVIVING ROUGH MUTANTS; D. CULTUTING THE SEPARATED MULTANTS; E. HARVESTING THE CELLS OF THE CULTURED MUTANTS; F. SUSPENDING THE HARVESTED CELLS IN A PROTECTIVE LIQUID MEDIUM CONSISTING ESSENTIALLY OF A DISPERSION OF SOLID CARRIER MATERIAL IN A VOLATILE LIQUID TO FORM A SUSPENSION; AND G. VOLATILIZING SAID LIQUID FROM THE SOLIDS IN SAID SUSPENSION,
Claim 5
Dependent Claim
110 words
An oral typhoid vaccine prepared by the method of claim 1 and consisting essentially of an intimate mixture of a pharmaceutically acceptable carrier and of live cells of at least one stable, non-virulent deletion mutant of a virulent parent strain of Salmonella typhi, said at least one mutant being free from uridine disphosphogalactose-4-epimerase activity and having a galactokinase activity and a galactose-1-phosphate uridylyltransferase activity not substantially greater than 10% of the galactokinase activity and galacto-1-phosphate uridylyl-transferase activity of said parent strain, the mount of said live cells being sufficient to improve the resistance of a person to infection with Salmonella typhi after oral ingestion of said vaccine by said person.
Claim 6
Dependent Claim
19 words
A vaccine as set forth in claim 2 wherein said virulent strain has the aNtigenic structure 9, 12, Vi:d.
Claim 7
Dependent Claim
24 words
A vaccine as set forth in claim 2 wherein said virulent strain is Salmonella typhi AMC 42-A-63, AMC 42-A-58, or AMC strain Boxhill 58/V.
Claim 8
Dependent Claim
12 words
A vaccine as set forth in claim 2 in dosage unit form.
Claim 9
Dependent Claim
17 words
A vaccine as set forth in claim 2, wherein said virulent strain is Salmonella typhi Ty 2.
Claim 10
Dependent Claim
13 words
A vaccine as set forth in claim 2, wherein said carrier is solid.
Claim 11
Dependent Claim
20 words
A vaccine as set forth in claim 7, further comprising an ingestible liquid, said mixture being dispersed in said liquid.
References Cited (Backward Citations)
CA765378A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1977-12-23 | 1978-06-24 | 1978-12-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1981-12-23 | 1982-06-24 | 1982-12-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1985-12-23 | 1986-06-24 | 1986-12-24 | $7700.00 | Window Closed / Lapsed |